Generated by AI
Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease. The company develops therapies designed to deliver ribonucleic acid medicines directly to cardiac tissue, using a proprietary delivery platform that combines tissue-selective targeting with oligonucleotide precision. Its current pipeline centers on rare genetic cardiomyopathies, including ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. Atrium Therapeutics also advances research programs aimed at additional rare cardiac conditions, reflecting its focus on genetically defined diseases with significant unmet medical need. Based in San Diego, California, Atrium Therapeutics operates as a specialist developer in the broader biotechnology sector, with a business model centered on translating RNA science into potential treatments for inherited heart disorders.
Website10578 Science Center Drive
San Diego, CA, 92121
United States
The latest articles about RNA.
The failure of a neuromuscular treatment is a blow to the drugmaker’s efforts to revive its growth prospects.
Summary of Mar 6's posts. Generated by AI.
Summary of Nov 7's posts. Generated by AI.
Summary of Feb 27's posts. Generated by AI.
Summary of Mar 6's posts. Generated by AI.
Investors talking about RNA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.